MINI LONG - VERTEX PHARMACEUTICALS | Delayed Deutsche Boerse AG 01:43:37 13/05/2024 pm IST | ||
| 21.09 EUR | +1.49% |
|
| Current month | +11.42% | ||
| 1 month | +10.95% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/24/13 | 21.09 | +1.49% | 0 |
| 10/24/10 | 20.78 | +0.63% | 0 |
| 09/24/09 | 20.65 | -1.34% | 0 |
| 08/24/08 | 20.93 | +4.03% | 0 |
| 07/24/07 | 20.12 | +4.14% | 0 |
Delayed Quote Deutsche Boerse AG
Last update May 13, 2024 at 01:43 pm IST
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Citi
|
| WKN | KA4XNU |
| ISIN | DE000KA4XNU0 |
| Date issued | 04/10/2019 |
| Strike | 196.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.81 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 23.57 € |
|---|---|
| Lowest since issue | 1.17 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
422.8
USD
Average target price
462.1
USD
Spread / Average Target
+9.30%
- Stock Market
- Certificates
- Certificat